2. Inflammation/Immunology

Inflammation/Immunology

Inflammation/Immunology

Related Products

PDF 93.1 MB

The diseases caused by disorders of the immune system fall into two broad categories: immunodeficiency and autoimmunity. Immunotherapy is also often used in the immunosuppressed (such as HIV patients) and people suffering from other immune deficiencies or autoimmune diseases. This includes regulating factors such as IL-2, IL-10, IFN-α. Infection with HIV is characterized not only by development of profound immunodeficiency but also by sustained inflammation and immune activation. Chronic inflammation as a critical driver of immune dysfunction, premature appearance of aging-related diseases, and immune deficiency.

Cat. No. 상품명 CAS No. Purity 화학구조
  • HY-162754
    LMP7/LMP2-IN-1 3053755-09-9 98%
    LMP7/LMP2-IN-1 (Compound 19) is the orally active inhibitor for immunoproteasome subunits LMP7 and LMP2 with IC50 of 257 and 10 nM. LMP7/LMP2-IN-1 reduces the generation of antibody, downregulates the cells in spleen germinal center B and in plasma in NP-OVA-immunized mice, and can be used in research about autoimmune diseases.
    LMP7/LMP2-IN-1
  • HY-162797
    PDE4-IN-18 98%
    PDE4-IN-18 (compound 1l) is a PDE4 inhibitor (IC50=1.55 μM) with anti-inflammatory activity. PDE4-IN-18 exerts anti-inflammatory effects by reducing excessive immune cell infiltration and intestinal membrane formation, as well as reducing the mRNA expression of pro-inflammatory cytokines (such as TNF-α and IL-6) in synovial tissue. PDE4-IN-18 can be used in the study of rheumatoid arthritis and psoriasis.
    PDE4-IN-18
  • HY-162805
    iNOS/TopoI-IN-1 98%
    iNOS/TopoI-IN-1 (compound AuL9) is a multi-target hybrid molecule with anti-tumor, anti-inflammatory and antioxidant activities. iNOS/TopoI-IN-1 inhibits the growth of breast cancer cells MCF-7 and MDA MB-231 in vitro with IC50 of 3.5 μM and 6.3 μM, respectively, and induces DNA damage and apoptosis of breast cancer cells by inhibiting human topoisomerase I (TopoI) (Ki=2.72 μM). In addition, NOS/TopoI-IN-1 inhibits the expression of iNOS by inhibiting the activation of NF-kB (Ki=1.49 μM).
    iNOS/TopoI-IN-1
  • HY-162845
    TLR7/8 agonist 11 98%
    TLR7/8 agonist 11 (compound 30) is a potent agonist of hTLR7 and hTLR8, with EC50s of 31.1 nM and 13.1 nM, respectively. TLR7/8 agonist 11 plays an important role in adaptive and innate immune responses.
    TLR7/8 agonist 11
  • HY-162846
    NLRP3-IN-44 3040298-34-5 98%
    NLRP3-IN-44 (compound P33) is a potent and orally active (approximately 62%) inhibitor of NLRP3, with the Kd of 17.5 nM. NLRP3-IN-44 plays an important for studying NLRP3 inflammasome-mediated diseases.
    NLRP3-IN-44
  • HY-162850
    DOR agonist 2 1212540-02-7 98%
    DOR agonist 2 (Compound 3) is a Delta Opioid Receptor agonist. DOR agonist 2 can inhibit the expression of TNF-α, prevent NF-κB transport to the nucleus, and activate the G protein-mediated ERK1/2 pathway. DOR agonist 2 can be used in the study of neurodegenerative diseases.
    DOR agonist 2
  • HY-162861
    3-Methyl-chuangxinmycin 98%
    3-Methyl-chuangxinmycin is an antibiotic. 3-Methyl-chuangxinmycin can affect the translation process in bacteria and mammalian cells by inhibiting the enzyme that synthesizes tryptophan tRNA (TrpRS). 3-Methyl-chuangxinmycin can downregulate genes related to interferon, TNF, and inflammatory responses in RDEB_L1 cells.
    3-Methyl-chuangxinmycin
  • HY-162901
    NLRP3-IN-48 98%
    NLRP3-IN-48 is an NLRP3 inhibitor. NLRP3-IN-48 targets the NLRP3 protein, affecting the assembly of the NLRP3 inflammasome and thereby inhibiting its activation. NLRP3-IN-48 has anti-inflammatory activity in a mouse model of acute colitis induced by DSS.
    NLRP3-IN-48
  • HY-162910
    HDAC-IN-79 98%
    HDAC-IN-79 (compound 4) is an orally active dual xanthine oxidase-HDAC inhibitor (Xanthine oxidase: IC50=6.6 nM; HDAC1: IC50=134 nM; HDAC2: IC50=284 nM; HDAC3: IC50=173 nM; HDAC6: IC50=1.32 nM;), with significant in vivo anti-hyperuricemia and anti-tumor activities. HDAC-IN-79 is the most potent cell growth inhibitor (IC50=0.706 μM) of leukemia HL60 cells, induces apoptosis and autophagy, and can regulate the expression levels of signature biomarkers associated with intracellular HDAC inhibition.
    HDAC-IN-79
  • HY-16291A
    APTO-253 hydrochloride 1691221-67-6 98%
    APTO-253?(LOR-253) hydrochloride is a small molecule that inhibits c-Myc expression, stabilizes G-quadruplex DNA and induces cell cycle arrest and apoptosis in acute myeloid leukemia cells. APTO-253?hydrochloride mediates anticancer activity via induction of Kruppel-like factor 4?(KLF4)?tumor suppressor. APTO-253?hydrochloride exhibits antiarthritic activity.
    APTO-253 hydrochloride
  • HY-162929
    TP-DEA2 2871739-84-1 98%
    TP-DEA2, a predictable-release Triptolide (HY-32735) prodrug, block Bleomycin-induced pulmonary fibrosis and inflammation. TP-DEA2 significantly inhibits α-SMA production.
    TP-DEA2
  • HY-162963
    DN203316 2982696-04-6 98%
    DN203316 (PPARδ agonist 11) is a potent, selective, orally active PPARδ agonist (EC50 = 20 nM) with high selectivity over PPARα and PPARγ. DN203316 suppresses NF-κB-mediated inflammatory signaling, inhibits ferroptosis by upregulating xCT and GPX4, and attenuates STING-TBK1-IRF3-driven fibrogenic responses. DN203316 is useful for research on inflammatory disorders, metabolic dysfunction-associated steatohepatitis (MASH), and liver fibrosis.
    DN203316
  • HY-162967
    MS8588 3060519-94-7 98%
    MS8588 is a deubiquitinase-targeting chimera (DUBTAC) against cGAS. MS8588 induces targeted stabilization of cGAS, thereby activating downstream signaling pathways. MS8588 activates the cGAS/STING/IRF3 innate immune signaling pathway. MS8588 exhibits antitumor activity.
    MS8588
  • HY-162978
    DGAT2-IN-3 3037141-61-7 98%
    DGAT2-IN-3 (compound 9) is a DGAT2 inhibitor, with IC50 of 0.4 nM. DGAT2-IN-3 can be used in the research of steatohepatitis, diabetes and cardiovascular diseases.
    DGAT2-IN-3
  • HY-163008
    Dicamba-5-aminopentanoic acid 2339488-53-6 98%
    Dicamba-5-aminopentanoic acid (DCc) is an immunizing and heterologous hapten, designed using the carboxylic acid group of dicamba to introduce a spacer arm for a better exposure of the herbicide's structure.
    Dicamba-5-aminopentanoic acid
  • HY-163012
    Dicamba-6-amino-6-oxohexanoic acid 98%
    Dicamba-6-amino-6-oxohexanoic acid (DCh) is an immunizing and heterologous hapten, activated before removing the 1-tert-butyl-benzoate moiety.
    Dicamba-6-amino-6-oxohexanoic acid
  • HY-163014
    Dicamba 1-azidopropane 2892008-32-9 98%
    Dicamba 1-azidopropane (DCn) is an immunizing and heterologous hapten. Dicamba 1-azidopropane can be used to generate monoclonal antibodies specific of Dicamba.
    Dicamba 1-azidopropane
  • HY-163021
    Simeton-acetic acid 2222775-69-9 98%
    Simeton-acetic acid is an immunizing hapten that can be coupled with bovine serum albumin. Simeton-acetic acid-BSA can produce PcAbs obtained with titer 1.0×103.
    Simeton-acetic acid
  • HY-163024
    Atrazine-3-mercaptopropanoic acid 125454-31-1 98%
    Atrazine-3-mercaptopropanoic acid is a hapten. The IC50 value of polyclonal antibody (PcAb) 1 with coating Atrazine-3-mercaptopropanoic acid is 7.5 ng/mL.
    Atrazine-3-mercaptopropanoic acid
  • HY-163025
    Cyanazine-3-mercaptopropanoic acid 98%
    Cyanazine-3-mercaptopropanoic acid (compound 6), a coating hapten, is a stable carrier-hapten complex. Polyclonal antibody obtained were with a high titer, with the IC50 of 10.2 ng/mL for Cyanazine-3-mercaptopropanoic acid.
    Cyanazine-3-mercaptopropanoic acid
Cat. No. 상품명 / Synonyms Application Reactivity